Casdatifan is a second-generation, orally bioavailable HIF-2α inhibitor developed by Arcus Biosciences.
LY104 is a novel compound designed as a potential therapeutic for chronic obstructive pulmonary disease (COPD), a severe inflammatory airway condition.
Lunresertib (RP-6306) is the first selective and orally bioavailable inhibitor of PKMYT1, a serine/threonine kinase that regulates CDK1 activity through phosphorylation.
Arformoterol is the (R, R)-enantiomer of formoterol, a highly potent long-acting β₂-adrenergic agonist used primarily for treating respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma.
GDC-8264 is a selective inhibitor of RIPK1 (receptor-interacting protein kinase 1), a key regulator of inflammation and cell death pathways. Developed by Genentech, GDC-8264 is being investigated for the prevention of cardiac surgery-associated acute kidney injury (CS-AKI) and other major adverse kidney events (MAKE). Its pharmacological action targets inflammatory responses in autoimmune and neurodegenerative diseases.
Dactolisib is a “first-in-class” dual PI3K/mTOR inhibitor developed by Novartis. Its dual-target mechanism reduces compensatory signaling activation caused by single-target inhibition, providing a potential therapeutic strategy for patients with solid tumors (e.g., breast cancer, renal cell carcinoma) and hematological malignancies harboring PI3K pathway abnormalities.